SFC to develop insulin pump with open-protocol communication

by Talk Business & Politics staff (staff2@talkbusiness.net) 169 views 

Fayetteville-based medical technology company SFC Fluidics LLC recently established a partnership with JDRF to develop an insulin patch pump with open-protocol communication.

The industry discovery and development partnership follows JDRF’s two-year funding agreement with SFC announced earlier this year for the development of a single pod Automated Insulin Delivery device. With the partnership, JDRF, a global organization that funds type 1 diabetes research, will provide funding to SFC with the goal to develop and deliver to market a fully interoperable, open-protocol insulin pump.

In 2017, JDRF launched its open-protocol automated insulin delivery systems initiative and looked to work with stakeholders to understand the regulatory and liability implications related to open-protocol automated insulin delivery systems. The organization wants to determine which of the system’s components could safely and seamlessly interoperate and to accelerate their market availability.

Insulin-dependent diabetes affects more than 6 million Americans, and most aren’t reaching clinical targets for optimal glucose levels. The patch pump SFC will develop is expected to operate on its own platform and be able to communicate with other approved vehicles.

“There is a passionate group of people behind a patient-driven ecosystem, using do-it-yourself approaches to develop solutions to meet their needs,” said Anthony Cruz, CEO of SFC Fluidics. “We believe SFC’s unique pumping technology will provide new options for them to live the lifestyle that suits them the best. With our partnership with JDRF, we will bring new and innovative solutions to the diabetes community.”

Daniel Finan, JDRF research director, was excited about the partnership with SFC. “We are hopeful that solutions such as this will greatly expand choice in the marketplace, increase adoption of advanced, life-improving technologies among people with (type 1 diabetes) and accelerate the cadence of innovation in these treatment options,” he said.